OpportunityTitle: DoD Breast Cancer, Transformative Breast Cancer Consortium Development Award
Description: The FY23 Transformative Breast Cancer Consortium Development Award is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). This is a development award and is a separate mechanism from the full consortium award. Recipients of the FY23 Transformative Breast Cancer Consortium Development Award are expected to submit an application to compete for the full Transformative Breast Cancer Consortium Award anticipated to be offered in a future fiscal year(s). However, it is not necessary to receive a development award in order to apply for a full consortium award in the future. For FY23, investigators may be named as Consortium Director on an application submitted to either (but not both) of these mechanisms. Detailed information on the FY23 Transformative Breast Cancer Consortium Award is available under a separate program announcement (HT945-23-BCRP-TBCCA). The FY23 Transformative Breast Cancer Consortium Development Award provides support to: &#183; Develop the infrastructure of a multi-institutional research team inclusive of scientists, clinicians, and breast cancer advocates (e.g., building appropriate collaborations, outlining integration, research management, administrative management, and communication plans, and devising an intellectual property plan) &#183; Generate necessary preliminary data to serve as proof of concept or for project integration &#183; Acquire research resources &#183; Develop a framework of necessary statistical analyses Breast cancer consumer advocates must be active participants in the development and execution of the Transformative Breast Cancer Consortium Development Award. A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer- Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY23 BCRP priorities.
GrantorContactEmailDescription: CDMRP Help Desk
GrantorContactText: CDMRP Help Desk &lt;br/&gt;Phone:      301-682-5507 &lt;br/&gt;Email:       help@eBRAP.org